# US 2004/0001848 A1 · Method of producing disease-specific antigens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0001848 A1
- Document ID: US20040001848A1
- Status: Published application
- Kind: A1
- Application number: 10/231,213
- Filed: 2002-08-28
- Published: 2004-01-01
- Earliest claimed: 2002-03-01
- Inventors: Szu-Yi Chou
- Web page: https://patentgrep.com/patent/US20040001848A1

## CPC

- C12N 9/1044: {Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII}
- A61K 39/0007: {Nervous system antigens; Prions}
- A61K 39/0011: {Cancer antigens}
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K 14/4711: {Alzheimer's disease; Amyloid plaque core protein}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/64: {characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Embodiments of the invention generally provide methods and compositions for producing disease-specific antigens. In one aspect, the invention provides a method of producing an antigen specific for Alzheimer's disease. In another aspect, the invention provides a method of producing a polyvalent antigen for two or more diseases. In yet another aspect, compositions of antigens are prepared and provided to immunize animals and induce strong immune responses.

## Claims

### Claim 1

A method for producing an antigen specific for one or more diseases, comprising:
obtaining one or more disease-specific compounds for each of the one or more diseases;
preparing the obtained one or more disease-specific compounds relating to the one or more diseases in a cross-linking solution;
combining the prepared disease-specific compounds with a biological agent into a mixture;
incubating the mixture at a temperature for a period of time sufficient to effect cross-linking of the disease-specific compounds into a plurality of cross-linked products; and
providing the plurality of the cross-linked products as the antigen.

### Claim 2 (depends on 1)

The method of claim 1, wherein the obtaining step further comprises attaching to the disease-specific compounds one or more amino acid residues that are reactive to the biological agent.

### Claim 3 (depends on 43)

The method of claim 43, wherein the one or more amino acid residues are attached by synthesizing the disease-specific compounds with additional one or more amino acid residues.

### Claim 4 (depends on 1)

The method of claim 1, further comprising administering a therapeutically safe and effective amount of the antigen to an animal.

### Claim 5 (depends on 1)

The method of claim 1, wherein the animal has the one or more diseases.

### Claim 6 (depends on 1)

The method of claim 1, wherein the antigen is administered to the animal to prevent the occurrence of the one or more disease.

### Claim 7 (depends on 1)

The method of claim 1, wherein the diseases are selected from a group consisting of viral infections, bacterial infections, fungal infections, cancers, virus-induced caners, oncogene-induced cancers, tumor associated antigens-induced cancers, parasite infections, Alzheimer's diseases, and combinations thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the one or more disease-specific compounds are selected from a group consisting of polypeptides, naturally occurring proteins, polyamino acids, cell-membrane-associated proteins, tumor-associated antigens, cytokines, cytokine receptors, bacterial toxins, whole bacterial cells, viral coat proteins, whole viruses, viral glycoproteins, cell wall-derived coat proteins, peptides, synthetic peptides, and modifications and derivatives of the aforementioned compounds.

### Claim 9 (depends on 1)

The method of claim 1, wherein the one or more disease-specific compounds for each of the one or more diseases comprises one or more glutamine residues.

### Claim 10 (depends on 1)

The method of claim 1, wherein the one or more disease-specific compounds for each of the one or more diseases comprises two or more compounds.

### Claim 11 (depends on 1)

The method of claim 1, further comprising monitoring a change of color in the mixture, wherein the mixture comprises an absorbance value (OD value) of about 0.1 or more at a wavelength from about 400 to about 500.

### Claim 12 (depends on 1)

The method of claim 1, wherein the cross-linking solution comprises at least one reducing agent, deionized water, a pH buffering agent for adjusting the pH of the cross-linking solution, and combinations thereof.

### Claim 13 (depends on 1)

The method of claim 1, wherein the biological agent is selected from a group consisting of transglutaminases, oxidases, sulfhydryl oxidases, lipoxygenases, polyphenol oxidases, tyrosinase, laccases, lysyl oxidases, peroxidase, isomerases, protein disulfide-isomerases, reductases, protein-disulfide reductases, and combinations thereof.

### Claim 14 (depends on 1)

The method of claim 1, wherein the biological agent is a recombinant microbial transglutaminase.

### Claim 15 (depends on 1)

A purified antibody that binds specifically to the antigen of claim 1.

### Claim 16 (depends on 1)

An antigen composition prepared in accordance with the method of claim 1.

### Claim 17 (depends on 1)

A pharmaceutical composition comprising the antigen of claim 1.

### Claim 18

A method for producing an antigen relating to Alzheimer's disease, comprising:
obtaining at least one Alzheimer's related peptide;
preparing the at least one Alzheimer's related peptide in a cross-linking solution;
combining the at least one Alzheimer's related peptide with a biological agent into a mixture;
incubating the mixture at a temperature for a period of time sufficient to effect cross-linking of the at least one Alzheimer's related peptide into a plurality of cross-linked products; and
providing the cross-linked products to be used as the antigen.

### Claim 19 (depends on 18)

The method of claim 18, wherein the at least one Alzheimer's related peptide is selected from a group consisting of β-amyloid peptide, natural occurring peptide having at least one glutamine residue, synthetic peptide having at least one glutamine residue, synthetic peptide having at least one glutamine residue at one terminus and at least one lysine residue at the other terminus, and combinations of.

### Claim 20 (depends on 18)

The method of claim 18, wherein the at least one Alzheimer's related peptide in the cross-linking solution comprises at least one glutamine residue.

### Claim 21 (depends on 18)

The method of claim 18, wherein the at least one Alzheimer's related peptide in the cross-linking solution comprises two or more peptides.

### Claim 22 (depends on 18)

The method of claim 18, further comprising purifying the plurality of the cross-linked products after the incubating step.

### Claim 23 (depends on 18)

The method of claim 18, further comprising monitoring a change of color in the mixture, wherein the mixture comprises an absorbance value (OD value) of about 0.1 or more at a wavelength from about 400 to about 500.

### Claim 24 (depends on 18)

The method of claim 18, wherein the cross-linking solution comprises at least one reducing agent, deionized water, a pH buffering agent for adjusting the pH of the cross-linking solution, and combinations thereof.

### Claim 25 (depends on 18)

The method of claim 18, wherein the biological agent is selected from a group consisting of transglutaminases, oxidases, sulfhydryl oxidases, lipoxygenases, polyphenol oxidases, tyrosinase, laccases, lysyl oxidases, peroxidase, isomerases, protein disulfide-isomerases, reductases, protein-disulfide reductases, and combinations thereof.

### Claim 26 (depends on 18)

The method of claim 18, wherein the biological agent is a recombinant microbial transglutaminase.

### Claim 27 (depends on 18)

The method of claim 18, further comprising administering a therapeutically safe and effective amount of the antigen to an animal.

### Claim 28 (depends on 27)

The method of claim 27, wherein the animal has Alzheimer's disease.

### Claim 29 (depends on 18)

A purified antibody that binds specifically to the antigen of claim 18.

### Claim 30 (depends on 18)

An antigen composition prepared in accordance with the method of claim 18.

### Claim 31 (depends on 18)

A pharmaceutical composition comprising the antigen of claim 18.

### Claim 32

A method for producing an antigen relating to at least one tumor-associated disease, comprising:
obtaining at least one tumor-specific compound relating to the at least one tumor-associated disease;
preparing the at least one tumor-specific compound in a cross-linking solution;
incubating the at least one tumor-specific compound with a biological agent into a mixture;
incubating the mixture at a temperature for a period of time sufficient to effect cross-linking of the at least one tumor-specific compound into a plurality of cross-linked products; and
providing the cross-linked products to be used as the antigen.

### Claim 33 (depends on 32)

The method of claim 32, further comprising purifying the plurality of the cross-linked products after the incubating step.

### Claim 34 (depends on 32)

The method of claim 32, further comprising administering a therapeutically safe and effective amount of the antigen to an animal.

### Claim 35 (depends on 34)

The method of claim 34, wherein the animal has the tumor-associated disease.

### Claim 36 (depends on 34)

The method of claim 34, wherein the antigen is administered to the animal to prevent the occurrence of the tumor-associated disease.

### Claim 37 (depends on 32)

The method of claim 32, wherein the at least one tumor-specific compound is selected from a group consisting of polypeptides, naturally occurring proteins, polyamino acids, cell-membrane-associated proteins, tumor-associated antigens, cytokines, cytokine receptors, bacterial toxins, whole bacterial cells, viral coat proteins, whole viruses, viral glycoproteins, cell wall-derived coat proteins, peptides, synthetic peptides, and modification and derivatives of the aforementioned compounds.

### Claim 38 (depends on 32)

The method of claim 32, wherein the at least one tumor-specific compound in the cross-linking solution comprises at least one glutamine residue.

### Claim 39 (depends on 32)

The method of claim 32, wherein the at least one tumor-specific compound in the cross-linking solution comprises two or more compounds.

### Claim 40 (depends on 32)

The method of claim 32, further comprising monitoring a change of color in the mixture, wherein the mixture comprises an absorbance value (OD value) of about 0.1 or more at a wavelength from about 400 to about 500.

### Claim 41 (depends on 32)

The method of claim 32, wherein the cross-linking solution comprises at least one reducing agent, deionized water, a pH buffering agent for adjusting the pH of the cross-linking solution, and combinations thereof.

### Claim 42 (depends on 32)

The method of claim 32, wherein the biological agent is selected from a group consisting of transglutaminases, oxidases, sulfhydryl oxidases, lipoxygenases, polyphenol oxidases, tyrosinase, laccases, lysyl oxidases, peroxidase, isomerases, protein disulfide-isomerases, reductases, protein-disulfide reductases, and combinations thereof.

### Claim 43 (depends on 32)

The method of claim 32, wherein the biological agent is a recombinant microbial transglutaminase.

### Claim 44 (depends on 32)

A purified antibody that binds specifically to the antigen of claim 32.

### Claim 45 (depends on 32)

An antigen composition prepared in accordance with the method of claim 32.

### Claim 46 (depends on 32)

A pharmaceutical composition comprising the antigen of claim 32.

### Claim 47

A method for producing a polyvalent antigen for two or more tumor-associated diseases using immunotherapy, comprising:
obtaining at least one tumor-specific compound for each of the two or more tumor-associated diseases;
preparing the obtained two or more tumor-specific compounds relating to the two or more tumor-associated diseases in a cross-linking solution;
combining the prepared two or more tumor-specific compounds with a biological agent into a mixture;
incubating the mixture at a temperature for a period of time sufficient to effect cross-linking of the two or more tumor-specific compounds into a plurality of cross-linked products; and
providing the plurality of the cross-linked products as the polyvalent antigen.

### Claim 48 (depends on 47)

The method of claim 47, further comprising purifying the plurality of the cross-linked products after the incubating step.

### Claim 49 (depends on 47)

The method of claim 47, further comprising administering a therapeutically safe and effective amount of the polyvalent antigen to an animal.

### Claim 50 (depends on 49)

The method of claim 49, wherein the animal has the two or more tumor-associated diseases.

### Claim 51 (depends on 49)

The method of claim 49, wherein the antigen is administered to the animal to prevent the occurrence of the two or more tumor-associated disease.

### Claim 52 (depends on 47)

The method of claim 47, wherein the at least one tumor-specific compound is selected from a group consisting of polypeptides, naturally occurring proteins, polyamino acids, cell-membrane-associated proteins, tumor-associated antigens, cytokines, cytokine receptors, bacterial toxins, whole bacterial cells, viral coat proteins, whole viruses, viral glycoproteins, cell wall-derived coat proteins, peptides, synthetic peptides, and modifications and derivatives of the aforementioned compounds.

### Claim 53 (depends on 47)

The method of claim 47, wherein the at least one tumor-specific compound for each of the two or more tumor-associated diseases comprises at least one glutamine residue.

### Claim 54 (depends on 47)

The method of claim 47, wherein the at least one tumor-specific compound for each of the two or more tumor-associated diseases comprising two or more compounds.

### Claim 55 (depends on 47)

The method of claim 47, wherein the biological agent is selected from a group consisting of transglutaminases, oxidases, sulfhydryl oxidases, lipoxygenases, polyphenol oxidases, tyrosinase, laccases, lysyl oxidases, peroxidase, isomerases, protein disulfide-isomerases, reductases, protein-disulfide reductases, and combinations thereof.

### Claim 56 (depends on 47)

A purified antibody that binds specifically to the polyvalent antigen of claim 47.

### Claim 57 (depends on 47)

A polyvalent antigen composition prepared in accordance with the method of claim 47.

### Claim 58 (depends on 47)

A pharmaceutical composition comprising the polyvalent antigen of claim 47.

### Claim 59

An antigen composition, comprising:
a plurality of cross-linked products prepared by attaching one or more amino acid residues to a compound and combining the compound with a solution of a biological agent, having a biological activity for the one or more amino acid residues, in a cross-linking solution into a mixture at a temperature for a period of a sufficient time.

### Claim 60 (depends on 59)

The antigen composition of claim 59, further comprising another compound selected from the group consisting of conjugate compound, co-stimulating factor for immune response, DNA vaccine, and combinations thereof, for promoting immune responses.

### Claim 61 (depends on 59)

The antigen composition of claim 59, wherein the compound in the cross-linking solution comprises two or more compounds.

### Claim 62 (depends on 59)

The antigen composition of claim 59, wherein the biological agent is selected from a group consisting of transglutaminases, oxidases, sulfhydryl oxidases, lipoxygenases, polyphenol oxidases, tyrosinase, laccases, lysyl oxidases, peroxidase, isomerases, protein disulfide-isomerases, reductases, protein-disulfide reductases, and combinations thereof.

### Claim 63 (depends on 59)

The antigen composition of claim 59, wherein the biological agent is a recombinant microbial transglutaminase.

### Claim 64 (depends on 59)

The antigen composition of claim 59, further comprising monitoring a change of color in the mixture, wherein the mixture comprises an absorbance value (OD value) of about 0.1 or more at a wavelength from about 400 to about 500.
